Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Nov 6, 2016; 7(4): 550-555
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Table 1 Patient profile of primary eradication therapy
| PPI group | Vonoprazan group | |
| Average age | 62.8 (18-94) | 62.7 (22-89) |
| Gender (male:female) | 902:818 | 170:165 |
| PPI | ||
| Lansoprazole | 1206 | |
| Omeprazole | 0 | |
| Rabeprazole | 62 | |
| Esomeprazole | 452 | |
| Underlying disease | ||
| Chronic gastritis | 1362 | 255 |
| Peptic ulcer | 248 | 55 |
| After endoscopic therapy for early gastric cancer | 107 | 25 |
| Other | 3 | 0 |
- Citation: Yamada S, Kawakami T, Nakatsugawa Y, Suzuki T, Fujii H, Tomatsuri N, Nakamura H, Sato H, Okuyama Y, Kimura H, Yoshida N. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 2016; 7(4): 550-555
- URL: https://www.wjgnet.com/2150-5349/full/v7/i4/550.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i4.550